JAK 阻害薬と悪性腫瘍リスク: さまざまな疾患のメタ解析
Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049
The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.
June 2023
August 2022
バイオナイーブの活動性乾癬性関節炎患者におけるグセルクマブの健康状態に対する効果; フェーズ3無作為化プラセボ対照52週DISCOVER-2 試験
Adv Ther. 2022 Oct;39(10):4632-4644 doi: 10.1007/s12325-022-02269-0
In the latest study by Curtis, et al. guselkumab treatment regimens improved general HRQoL as measured by the EQ-5D-5L Index and EQ-VAS. In reaching this conclusion investigators aimed to determine the minimal important difference for both instruments and to understand the associations between patient-reported EQ-5D-5L Index and EQ-VAS scores as well as key PsA clinical features.
Keywords:
May 2022
Guselkumab for the Treatment of Crohn’s Disease: Induction Results From the Phase 2 GALAXI-1 Study
Gastroenterology 2023;165:1588 doi 10.1053/j.gastro.2022.01.047
Guselkumab induced greater clinical and endoscopic improvements in patients with Crohn’s disease versus placebo, with a favourable safety profile in this Phase 2 trial by Sandborn, et al.
Keywords:
November 2020
関節リウマチにおけるUpadacitinibの安全性プロファイル:SELECT フェーズIII 臨床試験からの統合解析
Ann Rheum Dis 2020 DOI:10.1136/annrheumdis-2020-218510
This integrated Phase III safety analysis of UPA showed that UPA had a similar profile to ADA and MTX for serious infections, malignancies, and thromboembolic events. Patients receiving UPA had increased risk of HZ and creatine phosphokinase elevation versus ADA.This integrated Phase III safety analysis of UPA examined >3500 RA patients and 4000 patient-years of exposure. Data were pooled from 3834 patients in SELECT-NEXT, SELECT-BEYOND, SELECT-MONOTHERAPY, SELECT-COMPARE and SELECT-EARLY studie...
Keywords:
October 2019
低疾患活動性のRA患者における疼痛緩和と機能改善に対するバ リシチニブとアダリムマブの効果: RA-BEAMからの探索的解析
J Clin Med. 2019 Sep 5;8(9). pii: E1394
Post hoc analyses from RA-BEAM concluded that BARI 4 mg QD or ADA 40 mg Q2W resulted in improvements in pain, physical function, fatigue and work productivity in patients with RA, independent of the treatment’s impact on inflammation. Among patients achieving remission or LDA, greater improvements in pain and physical function were seen with BARI than with ADA or PBO.Of 1010 patients included in the analysis at Week 24, 168 were in remission, 310 were in remission/LDA and 700 were not in remissi...
Keywords:
September 2018
関節リウマチ治療における生物学的製剤とJAK 阻害薬の単剤の有効性: システマティックレビュー
ADV Ther 2018; 35(10):1525–63 DOI: 10.1007/s12325-018-0757-2
The b/tsDMARDs evaluated in this systematic literature review (SLR) were shown to be efficacious as monotherapies, although combination therapies usually achieved better treatment outcomes.Current treatment guidelines recommend combining b/tsDMARDs with MTX in the treatment of RA; however, up to a third of patients are treated with monotherapy. While previous SLRs1–3 have compared the efficacy of b/tsDMARD mono- versus MTX combination therapy they covered a limited number of randomised controlle...
August 2013
Safety profile of protein kinase inhibitors in rheumatoid arthritis: a systematic review and meta-analysis
Ann Rheum Dis April 2013; doi:10.1136/annrheumdis-2012-203116
Salgado and colleagues conducted a systematic literature review of the safety profiles of protein kinase inhibitors (PKis) used for the treatment of rheumatoid arthritis (RA). Additionally, the study aims included identification of any class and molecule-related target and off-target adverse events. Data from 11,858 patients across 41 publications (phase 2 and 3 studies and two pooled analyses) were analysed. As well as published trials of PKi in RA, studies on healthy individuals and patients w...